Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Recruiting
LOCATIONS 1
Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Upmc Cancercenter, Pittsburgh, Pennsylvania, United States|Md Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|Chris Obrien Lifehouse, Camperdown, New South Wales, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Nucleus Network Pty Ltd, Melbourne, Victoria, Australia|Linear Clinical Research, Nedlands, Western Australia, Australia|Cliniques Universitaires Ucl Saint-Luc, Brussels, Belgium|Institut Jules Bordet Clinical Trials Conduct Unit, Brussels, Belgium|Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium|Ghent University Hospital, Ghent, Belgium|Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium|Complex Onclogy Center Plovdiv Eood, Plovdiv, Bulgaria|Complex Oncological Center - Ruse Eood, Ruse, Bulgaria|Shatod Dr Marko Marko - Varna Ltd, Varna, Bulgaria|Institut de Cancerologie de L Ouest - Site Paul Papin, Angers, France|Institut Bergonie, Bordeaux, France|Chu Hopital de La Timone, Marseille Cedex 5, France|Centre Eugene Marquis, Rennes, France|National Cancer Center Hospital East, Chiba, Japan|National Cancer Center Hospital, Tokyo, Japan|Multifield Clinical Hospital No 4, Dnipro, Ukraine|Ci of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharkiv, Ukraine|Kherson Regional Oncologic Dispensary, Kherson, Ukraine|Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Kryvyi Rih, Ukraine|Volyn Regional Oncological Dispensary, Lutsk, Ukraine|Rmi Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine|Cne Ccch of Uzh Cc Oncological Center, Uzhgorod, Ukraine|Medical Clinic Innovacia Llc, Vyshhorod, Ukraine
Interventional
Drug: INCB099280
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists